Quanterix Corporation Common Stock (QTRX) is a publicly traded Healthcare sector company. As of May 21, 2026, QTRX trades at $2.53 with a market cap of $118.71M and a P/E ratio of -1.08. QTRX moved +0.00% today. Year to date, QTRX is -60.81%; over the trailing twelve months it is -49.50%. Its 52-week range spans $2.40 to $15.67. Analyst consensus is neutral with an average price target of $4.00. Rallies surfaces QTRX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Quanterix Targets H2 2026 Cash-Flow Breakeven with $85M Synergies and $100M Cash: Quanterix reported a Q4 2025 adjusted EBITDA loss of $7.9 million, improving from the prior quarter, and targets $85 million in cost synergies by end-Q1 2026 to achieve cash flow breakeven in H2 2026. The company holds over $100 million in cash with zero debt and plans a steady cadence of assay launches throughout 2026.
| Metric | Value |
|---|---|
| Price | $2.53 |
| Market Cap | $118.71M |
| P/E Ratio | -1.08 |
| EPS | $-2.34 |
| Dividend Yield | 0.00% |
| 52-Week High | $15.67 |
| 52-Week Low | $2.40 |
| Volume | 1 |
| Avg Volume | 0 |
| Revenue (TTM) | $144.98M |
| Net Income | $-104.19M |
| Gross Margin | 44.22% |
2 analysts cover QTRX: 0 strong buy, 0 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is neutral. Average price target: $4.00.